Although the total number of stroke deaths declined by more than 50 percent between 1978 and 2006, racial disparities in stroke deaths have remained and efforts to eliminate health disparities have been unsuccessful. Between ages 45 and 65, blacks are 2 to 3 times more likely to die from stroke than whites, but we haven’t …
Read MoreCategory Archives: Study
Updated 2-17-12: Thank you for coming to this link from a myriad of places (many of which we cannot delete our postings from). The survey is now complete and the link has been turned off. But since you have an interest in atrial fibrillation, we hope that you'll stick around and spend some time checking …
Read MoreIn this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the …
Read MoreDr. John Mandrola, a cardiac electrophysiologist in Louisville, Kentucky, who blogs at Dr. John M, live-blogged the 2012 Boston Atrial Fibrillation Symposium. He has given us permission to reprint his blog posts for the afib community. You will find them here: Recap of Boston Atrial Fibrillation Symposium 2012 – Guest Posts by Dr. John Mandrola …
Read MoreResults from FAST, the first-ever randomized trial to compare the effectiveness of minimally invasive surgical ablation (also called the mini maze procedure) for atrial fibrillation and catheter ablation for afib, were presented at the recent American Heart Association meeting. The FAST study enrolled patients who had failed a previous catheter ablation procedure. The minimally invasive …
Read MoreThe Food and Drug Administration (FDA) approved the AtriCure Synergy Ablation System for the treatment of persistent and longstanding persistent atrial fibrillation in patients undergoing another heart surgery. The Synergy bipolar radiofrequency clamp is the only surgical ablation device with FDA approval for afib treatment. Learn more: FDA Advisory Panel Recommends, and FDA Approves, Bipolar …
Read MoreAt the American Heart Association Scientific Sessions 2011, Dr. Sanjiv Narayan presented the high success rate of the FIRM trial of focal and rotor catheter ablation for atrial fibrillation. Watch the video at: Atrial Fibrillation Focal and Rotor Catheter Ablations Show High Success Rates — Video Interview with Dr. Sanjiv Narayan About the FIRM Trial
Read MoreA recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read MoreAt the American Heart Association Scientific Sessions 2011, Dr. John Mandrola presented a poster on gender-specific results of atrial fibrillation ablation in a private practice setting. In this video interview with him about the poster, he mentioned that in his experience women appear to be more challenging to treat with atrial fibrillation ablation and do …
Read MoreFDA Panel Says Bipolar Radiofrequency Surgical Ablation Effective for Persistent Atrial Fibrillation
An FDA advisory panel voted that the overall benefits outweighed the risks in afib ablations using the AtriCure Synergy bipolar radiofrequency clamp. This was based on the results of the ABLATE clinical trial for ablation of persistent or longstanding persistent atrial fibrillation during other heart surgery. The panel recommended that the FDA approve it, setting …
Read More